Lipodystrophy is associated with a low rate of treatment failure in HIV-positive patients switched to atazanavir

J Acquir Immune Defic Syndr. 2005 May 1;39(1):125-6. doi: 10.1097/01.qai.0000160516.28204.ff.
No abstract available

Publication types

  • Letter

MeSH terms

  • Atazanavir Sulfate
  • HIV Seropositivity / drug therapy*
  • HIV-Associated Lipodystrophy Syndrome / epidemiology*
  • Humans
  • Oligopeptides / adverse effects
  • Oligopeptides / therapeutic use*
  • Pyridines / adverse effects
  • Pyridines / therapeutic use*
  • Switzerland / epidemiology
  • Treatment Failure
  • Treatment Refusal

Substances

  • Oligopeptides
  • Pyridines
  • Atazanavir Sulfate